检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:黄昊 陈忠华[1] 罗咏萍[1] Huang Hao;Chen Zhonghua;Luo Yongping(Department of Gastroenterology,Second People′s Hospital of Yibin,Yibin,Sichuan 644000,China)
机构地区:[1]宜宾市第二人民医院消化内科,四川宜宾644000
出 处:《四川医学》2021年第5期480-483,共4页Sichuan Medical Journal
摘 要:目的探索大剂量阿莫西林联合艾司奥美拉唑一线治疗幽门螺旋杆菌感染的安全性和有效性。方法选取2017年5月至2019年5月在我院确诊的幽门螺旋杆菌感染的初次治疗的患者154例,随机分为EA组(大剂量阿莫西林联合艾司奥美拉唑,EA方案)和EABC组(常规剂量阿莫西林四联方案,EABC方案),连续服用14 d,比较用药结束后4周幽门螺旋杆菌的根除率。结果141例患者完成了研究,EA组和EABC组按意向(ITT)分析幽门螺旋杆菌的根除率分别为84.0%和86.1%,按方案(PP)分析根除率分别为91.3%和94.4%,两组的根除率差异均无统计学意义(P>0.05)。EA组的不良反应明显少于EABC组(5.80%vs.16.67%,P=0.042)。结论大剂量阿莫西林联合艾司奥美拉唑方案可作为一线治疗幽门螺旋杆菌感染,而且不良反应较少,但需要较高的用药频次及足够的用药疗程。Objective To explored the safety and efficacy of high-dose amoxicillin combined with esomeprazole as the first-line treatment against helicobacter pylori infection.Methods 154 patients were diagnosed with helicobacter pylori infection and received first time treatment in our hospital during May 2017 and May 2019.These patients were randomly divided into EA group and EABC group,which assigned with 14 day high-dose dual therapy or conventional dose amoxicillin quadruple therapy,respectively.Helicobacter pylori eradication rates were compared 4 weeks after treatment.Results 141 patients completed the study,the eradication rates of the EA and EABC groups were 84.0%and 86.1%,respectively,by intention-to-treat(ITT)analysis,and 91.3%and 94.4%,respectively,by per-protocol(PP)analysis.They were not statistically different(P>0.05).The adverse event rate in EA group was significantly lower than EABC group(5.8%vs.16.67%,P=0.042).Conclusion High-dose amoxicillin combined with esomeprazole can be used as first-line treatment for Helicobacter pylori infection.It has fewer side effects,and requires higher frequency of medication and sufficient time of therapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15